McKenna H J
Immunex Corporation, Seattle, Washington 98101, USA.
Curr Opin Hematol. 2001 May;8(3):149-54. doi: 10.1097/00062752-200105000-00004.
Dendritic cells (DCs) are hematopoietic cells that initiate immune responses by presenting antigen to T cells. Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a primary growth factor for DCs in vitro, but recently it was recognized that other factors including flt3 ligand (FL) and G-CSF expand various DC subsets in vivo. DCs undergo a complex series of maturation and activation steps after they acquire antigen and before they can activate resting T cells. In addition, they must traffic to T-cell-rich areas of lymph nodes (LN) to achieve this. Each of these steps is tightly regulated, and in the last year progress has been made in identifying some of the key molecules involved in each of these steps. This progress will further the efforts underway to develop DCs as vaccine adjuvants.
树突状细胞（DCs）是造血细胞，通过向T细胞呈递抗原引发免疫反应。粒细胞-巨噬细胞集落刺激因子（GM-CSF）是体外DCs的主要生长因子，但最近人们认识到，包括fms样酪氨酸激酶3配体（FL）和粒细胞集落刺激因子（G-CSF）在内的其他因子可在体内扩增各种DC亚群。DCs在获取抗原后、激活静息T细胞之前要经历一系列复杂的成熟和激活步骤。此外，它们必须迁移至富含T细胞的淋巴结（LN）区域才能实现这一点。这些步骤中的每一步都受到严格调控，并且在过去一年里，在确定参与这些步骤的一些关键分子方面取得了进展。这一进展将推动正在进行的将DCs开发为疫苗佐剂的努力。
